Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination

References

• American Heart AssociationHeart Disease and Stroke Statistics: 2004 UpdateDallas, TexAmerican Heart Association2003
   Google Scholar
• JohnsonMLPietzKBattlemanDSPrevalence of comorbid hypertension and dyslipidemia and associated cardiovascular diseaseAm J Manag Care20041092693215617368
   PubMed Web of Science ®Google Scholar
• KannelWBRisk stratification in hypertension: new insights from the Framingham StudyAm J Hypertension2000133S10S
   PubMed Web of Science ®Google Scholar
• CowieMRSimultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pilltherapyInt J Clin Pract200559783984615963213
   PubMed Web of Science ®Google Scholar
• RosendorffCBlackHRCannonCPTreatment of hypertension in the prevention and management of ischemic heart diseaseCirculation20071152761278817502569
   PubMed Web of Science ®Google Scholar
• JacksonRLawesCMMBennerttDATreatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascularriskLancet200536543444115680460
   PubMed Web of Science ®Google Scholar
• MesserliFHWilliamsBRitzEEssential hypertensionLancet200737059160317707755
   PubMed Web of Science ®Google Scholar
• The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Guidelines for the management of arterial hypertensionEur Heart J2007281462153617562668
   PubMed Web of Science ®Google Scholar
• KostisBKThe importance of managing hypertension and dyslipidemia to decrease cardiovascular diseaseCardiovasc Drugs Ther20072129730917605096
   PubMed Web of Science ®Google Scholar
• BattlemanDSPetersonEDEstimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among US adults in 2000, utilizing data from the National Health and Nutrition Examination Survey [abstract]J Manag Care Pharm2004102186
   Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF health protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSFixed-dose combinations improve medication compliance: a meta-analysisAm J Med200712071371917679131
   PubMed Web of Science ®Google Scholar
• DeziiCMA retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertensionManag Care20009Suppl2611729417
   PubMedGoogle Scholar
• SimpsonSHEurichDTMajumdarSRA meta-analysis of the association between adherence to drug therapy and mortalityBMJ200633315E1E6
   Google Scholar
• BosworthHBDudleyTOlsenMKRacial differences in blood pressure control: potential explanatory factorsAm J Med200611970e9e1516431192
   PubMedGoogle Scholar
• BennerJSGlynnRJMogunHLong-term persistence in use of statin therapy in elderly patientsJAMA200228845546112132975
   PubMed Web of Science ®Google Scholar
• GerbinoPPShoheiberOAdherence patterns among patients treated with fixed dose combination versus separate antihypertensive agentsAm J Health Syst Pharm20074710391048
   Google Scholar
• WangPJBohnRLKnightENoncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factorsJ Gen Intern Med200217750451112133140
   PubMed Web of Science ®Google Scholar
• SchwartzJSMclaughlinTGriffisDAdherence to chronic therapy among patients treated for hypertension, dyslipidemia or both [abstract]J Am Coll Cardiol200341suppl A526A
   Google Scholar
• AvornJMonetteJLacourAPersistence of use of lipid-lowering medications: a cross-national studyJAMA1998279145814629600480
   PubMed Web of Science ®Google Scholar
• SafranDGNeumanPSchoenCPrescription drug coverage and seniors: findings from a 2003 national survey. Where do things stand on the eve of implementing the new Medicare Part D benefit? Data Watch. 2005;DOI 10.1377/hlthaff.W5.152.W5–152–W5–166.
   Google Scholar
• SchultzJSO’DonnellJCMcDonoughKLDeterminants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care populationAm J Manag Care20051130631215898219
   PubMed Web of Science ®Google Scholar
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC7 ReportJAMA20032892560257212748199
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults (Adult treatment panel III) final reportCirculation20021063143342112485966
   PubMed Web of Science ®Google Scholar
• PettittDKarterAJPengTYThe impact of concurrent dyslipidemia and diabetes on hypertension management and goal attainmentPoster presented at: Annual meeting of the Society of General Internal MedicineApril 30–May 3, 2003Vancouver, Canada
   Google Scholar
• BergJSDischlerJWagnerDJMedication compliance: a healthcare problemAnn Pharmacother199327supplS1S248400462
   PubMed Web of Science ®Google Scholar
• AndradeSEWalkerAMGottliebLKDiscontinuation of anti-hyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings?N Engl J Med1995332112511317700285
   PubMed Web of Science ®Google Scholar
• SimonsLALevisGSimonsJApparent discontinuation rates in patients prescribed lipid-lowering drugsMed J Aust19961642082118604188
   PubMed Web of Science ®Google Scholar
• MonaneMBohnRLGurwitzJHThe effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderlyAm J Hypertens1997106977049234822
   PubMed Web of Science ®Google Scholar
• McCombsJSNicholMBNewmanCMThe costs of interrupting antihypertensive drug therapy in a Medicaid populationMed Care1994322142268145599
   PubMed Web of Science ®Google Scholar
• KogutSJAndradeSEWilleyCNon-adherence as a predictor of anti-diabetic drug therapy intensificationPharmacoepidemiol Drug Saf20041359159815362081
   PubMed Web of Science ®Google Scholar
• BlackburnDFDobsonRTBlackburnJLAdherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardio vascular event: a retrospective cohort studyCan J Cardiol20052148548815917876
   PubMed Web of Science ®Google Scholar
• HoPMRumsfeldJSMasoudiFAEffect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitusArch Intern Med20061661836184117000939
   PubMed Web of Science ®Google Scholar
• KulkarniSPAlexanderKPLytleBLong-term adherence with cardiovascular drug regimensAm Heart J200615118519116368315
   PubMed Web of Science ®Google Scholar
• ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med20051651147115215911728
   PubMed Web of Science ®Google Scholar
• McKeageKMSiddiquiAAAmlodipine/atorvastatin fixed-dose combination. a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemiaAm J Cardiovasc Drugs200881516718303938
   PubMed Web of Science ®Google Scholar
• KassRSArenaJPDiMannoDBlock of heart calcium channels by amlodipine: influence of drug charge on blocking activityJ Cardiovasc Pharmacol198812suppl 7S45S492467128
   PubMed Web of Science ®Google Scholar
• Lipitor (atorvastatin calcium) TabletsUS Prescribing InformationNew York, NYPfizer Inc2004
   Google Scholar
• NewmanCBPalmerGSilbershatzHSafety of atorvastatin derived from analysis of 44 completed trials in 9416 patientsAm J Cardiol20039267067612972104
   PubMed Web of Science ®Google Scholar
• JukemaJWvan der HoornJWAmlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapyExpert Opin Pharmacother20045245946814996641
   PubMed Web of Science ®Google Scholar
• MasonRPA rational for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidenceCurr Drug Targets Cardiovasc Haematol Disord20055648950116503869
   PubMedGoogle Scholar
• LeibovitzEBeniashviliMZimlichmanRTreatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patientsAm J Hypertens200316(9 Pt 1):71571812944027
   PubMed Web of Science ®Google Scholar
• FogariRPretiPZoppiAEffects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patientsEur J Clin Pharmacol20066281782216896785
   PubMed Web of Science ®Google Scholar
• MalhotraHSGoaKLAtorvastatin: an updated review of its pharmacological properties and use in dyslipidaemiaDrugs200161121835188111693468
   PubMed Web of Science ®Google Scholar
• MurdochDHeelRCAmlodipine: a review of its pharmacological and pharmacookinetic properties, and therapeutic use in cardiovascular diseaseDrugs19914134785051711448
   PubMed Web of Science ®Google Scholar
• Pfizer Labs. Caduet (amlodipine besylate/atorvastatin calcium) tablets: description [online]. Available from URL: http://www.caduet.com
   Google Scholar
• BlankRLaSalleJReevesRSingle pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodpine/atorvastatin Gemini Study)J Clin Hypertens200575264273
   Google Scholar
• HobbsFDGensiniGManciniGBCan combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)Int J Cardiol200611024225016338012
   PubMed Web of Science ®Google Scholar
• FeldmanRMultiple risk intervention with a single-pill combination (amlodipine/atorvastatin) helps patients to attain recommended target levels for blood pressure and lipids (The JEWEL Program) [abstract no. P-129B]J Clin Hypertens200686457
   Google Scholar
• PrestonRAHarveyPHerfertOA randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of co-administered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: The Respond trialJ Clin Pharmacol2007471555156918048574
   PubMed Web of Science ®Google Scholar
• TseHFRoYMHowesLMultiple-risk intervention with single-pill amlodipine/atorvastatin therapy helps patients with diverse ethnicity attain recommended therapeutic goals for blood pressure and lipids (the GEMINI-AALA study) [abstract no. PO3–79]J Hypertens200624Suppl 6329
   Google Scholar
• FlackJMVictorRWatsonKAmlodipine/atorvastatin single pill improves goal attainment in the treatment of hypertension and dyslipidemia in African Americans: the CAPABLE trial [abstract]J Clin Hypertens200686456
   Google Scholar
• PatelBVLeslieRSFoodyJMAdherence with single pill amlodipine/atorvastatin vs a two pill regimenVasc Health Risk Manag20084367368118827917
   PubMedGoogle Scholar